For patients with chronic viral hepatitis B, if the patient develops facial darkness and grayish color, it is mostly considered to be related to the patient’s hepatitis virus infection, which is mostly considered to be due to the hepatitis B virus causing estrogen inactivation disorder in the body, resulting in reduced melatonin production in patients, causing the patient’s facial pigmentation, resulting in the patient’s facial darkness. In addition, for patients with hepatitis, if the virus is in the replication phase, it may also cause liver insufficiency and hepatocellular jaundice due to hepatocyte necrosis, resulting in yellowing and graying of the patient’s face. Patients need further blood tests for hepatitis B DNA and liver function to see if the virus is replicating, and if the virus is replicating and liver function is impaired, the primary treatment is active antiviral therapy, either oral medication or interferon injection for antiviral therapy. After active antiviral treatment and liver preservation therapy, the patient’s liver function will improve and the patient’s complexion will improve.